title: Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial.
abstract: OBJECTIVE
  The first-in-man ABSORB Cohort A trial demonstrated the bioresorption of the ABSORB BVS (Abbott Vascular, Santa Clara, CA, USA) at two years. This report describes the 4-year clinical outcomes.
  
  
  RESULTS
  The ABSORB Cohort A trial enrolled 30 patients with a single de novo native coronary artery lesion. Clinical follow-up was available in 29 patients since one patient withdrew consent after the six month follow-up. At four years, the hierarchical ID-MACE of 3.4% remained unchanged. Clopidogrel therapy had been discontinued in all patients.
  
  
  CONCLUSIONS
  Four-year clinical results demonstrate a sustained low MACE rate (3.4%) without any late complications such as stent thrombosis.
authors.affiliation: Jagiellonian University Medical College, Krakow, Poland. mcdudek@cyfronet.pl
authors.forename: Dariusz
authors.initials: D
authors.lastname: Dudek
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Onuma
authors.forename: John A
authors.initials: JA
authors.lastname: Ormiston
authors.forename: Leif
authors.initials: L
authors.lastname: Thuesen
authors.forename: Karine
authors.initials: K
authors.lastname: Miquel-Hebert
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Serruys
mesh_terms: D001807:Blood Vessel Prosthesis / Q000009:adverse effects; D015331:Cohort Studies; D003324:Coronary Artery Disease / Q000628:therapy*; D054855:Drug-Eluting Stents / Q000009:adverse effects; D000068338:Everolimus; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008137:Longitudinal Studies; D009203:Myocardial Infarction / Q000453:epidemiology; D012307:Risk Factors; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives*; D013927:Thrombosis / Q000453:epidemiology; D054457:Tissue Scaffolds / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000068338:Everolimus; D020123:Sirolimus